As the newest iterations of AlphaFold’s molecular modeling tool and ChatGPT’s language and coding models, among several others, lower the barriers for implementing AI applications at biotechs, the challenge for management teams shifts to separating hype from substance among internal investment options. This session will prioritize the productivity enhancements available now for biotechs already developing existing assets to help gather evidence and advance such assets toward approval faster and lower total development costs.​